Astrazeneca plc
NASDAQ: AZN
$77.99
-$0.19 (-0.2%)
Closing Price on June 28, 2024
AZN Articles
AstraZeneca has announced that the European Commission granted marketing authorization for two of its treatments: Zurampic for gout and Brilique for heart attack patients.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
Published:
Last Updated:
Stocks tanked on Friday but were indicated sharply higher on Tuesday after the three-day weekend and after China’s gross domestic product met expectations. While investors may feel that every...
Published:
Last Updated:
Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a new gout treatment.
Published:
Last Updated:
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Published:
Last Updated:
Wednesday's top analyst upgrades, downgrades and initiations include Aegerion Pharmaceuticals, Amazon.com, EMC, McDonald's, MetLife, Microsoft, SanDisk and Tyco International.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
Published:
Last Updated:
Monday's top analyst upgrades, downgrades and initiations include AeroVironment, Gold Fields, Marvell Technology, Nokia and Silver Wheaton.
Published:
Wednesday’s top analyst upgrades, downgrades and initiations include ARM Holdings, AT&T, Hasbro, Lending Club, PNC Financial Services, Vodafone and Walt Disney.
Published:
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.
Published:
Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United States.
Published:
The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late.
Published:
Drug giants Merck and Pfizer reported better-than-expected second-quarter 2014 results before markets opened Tuesday morning.
Published:
Last Updated:
Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance is that Pfizer may now simply be having an identity crisis.
Published: